Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study

Abstract Introduction Interleukin-1 receptor-associated kinase 4 (IRAK4) is expressed in various immune cells and regulates proinflammatory cytokine production. Its inhibition represents a novel, promising therapeutic option in the treatment of atopic dermatitis (AD). Zabedosertib (BAY1834845) is a...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Stefan J. Jodl, Margitta Worm, Frauke Friedrichs, Ulrike Heinzel-Pleines, Andrea Wagenfeld, Maximilian Feldmüller, Stefan Klein, Ruiping Zhang, Kaweh Shakery, Ruth D. Holzmann, Beate Rohde, Vidya Perera
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Adis, Springer Healthcare 2025-09-01
Seri Bilgileri:	Dermatology and Therapy
Konular:	Atopic dermatitis Controlled trial Interleukin-1 receptor-associated kinase 4 inhibitor IRAK4 Kinase inhibition Randomized
Online Erişim:	https://doi.org/10.1007/s13555-025-01505-z
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!